United Therapeutics Corporation $UTHR Shares Bought by Andra AP fonden

Andra AP fonden lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 33.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,904 shares of the biotechnology company’s stock after purchasing an additional 8,760 shares during the quarter. Andra AP fonden owned about 0.08% of United Therapeutics worth $18,912,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Toth Financial Advisory Corp lifted its holdings in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors acquired a new stake in United Therapeutics during the second quarter valued at approximately $30,000. Caitlin John LLC bought a new stake in United Therapeutics during the second quarter worth approximately $37,000. International Assets Investment Management LLC increased its holdings in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares in the last quarter. Finally, Cullen Frost Bankers Inc. lifted its position in shares of United Therapeutics by 3,333.3% during the 4th quarter. Cullen Frost Bankers Inc. now owns 103 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 100 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Up 0.1%

NASDAQ UTHR traded up $0.48 on Tuesday, hitting $493.58. 107,976 shares of the company’s stock traded hands, compared to its average volume of 514,729. The firm’s 50-day moving average price is $514.63 and its two-hundred day moving average price is $540.46. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The firm has a market capitalization of $21.17 billion, a PE ratio of 17.67, a P/E/G ratio of 2.48 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the business posted $6.41 EPS. The business’s revenue was down 1.9% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $545.80, for a total value of $5,185,100.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,111,995.40. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 355,553 shares of company stock valued at $185,195,396 over the last quarter. Company insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.